Michael Amoroso is a biotech CEO with significant operational experience leading organizations focused on cell and gene therapies. He brings extensive experience leading teams across research, clinical development, regulatory and medical affairs, and commercial operations, with direct operational experience in the U.S. and major world markets with a particular focus on oncology drugs, including CAR T cell therapies for hematologic malignancies. Prior to joining Precision, he was President and Chief Executive Officer of Abeona Therapeutics, Inc., a fully integrated gene and cell therapy company. Before this role, Mr. Amoroso served as Abeona’s Chief Commercial Officer and Chief Operating Officer, responsible for overseeing the operational management of Abeona, including research and clinical development, regulatory, medical, commercial, corporate affairs, and business development. Previously, Mr. Amoroso was the Senior Vice President and Chief Commercial Officer at Kite Pharma, Inc. He held various senior-level executive positions at leading biopharmaceutical companies, including Eisai Inc., Celgene Corporation, and began his biopharmaceutical career at Aventis (now Sanofi S.A.). Mr. Amoroso earned his Executive M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.
What is Michael Amoroso's net worth?
The estimated net worth of Michael Amoroso is at least $2.04 million as of February 18th, 2026. Mr. Amoroso owns 243,392 shares of Precision BioSciences stock worth more than $2,035,974 as of July 16th. This net worth approximation does not reflect any other investments that Mr. Amoroso may own. Learn More about Michael Amoroso's net worth.
How do I contact Michael Amoroso?
Has Michael Amoroso been buying or selling shares of Precision BioSciences?
Michael Amoroso has not been actively trading shares of Precision BioSciences over the course of the past ninety days. Most recently, Michael Amoroso sold 20,559 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.84, for a transaction totalling $78,946.56. Following the completion of the sale, the chief executive officer now directly owns 243,392 shares of the company's stock, valued at $934,625.28. Learn More on Michael Amoroso's trading history.
Who are Precision BioSciences' active insiders?
Are insiders buying or selling shares of Precision BioSciences?
In the last twelve months, Precision BioSciences insiders bought shares 5 times. They purchased a total of 11,181 shares worth more than $53,978.57. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 98,557 shares worth more than $407,257.82. The most recent insider tranaction occured on February, 18th when CEO Michael Amoroso sold 20,559 shares worth more than $78,946.56. Insiders at Precision BioSciences own 2.7% of the company.
Learn More about insider trades at Precision BioSciences. Information on this page was last updated on 2/18/2026.
